Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ionis Pharmaceuticals
Biotech
RNA biotech emerges with $52M and clinical rare disease asset
Arnatar currently touts seven assets, with six preclinical programs that range across cardiometabolic, inflammatory and CNS conditions.
Gabrielle Masson
Aug 25, 2025 10:13am
Ono pays $280M upfront for Ionis' phase 2 blood cancer med
Mar 12, 2025 6:30am
Arrowhead posts phase 3 data ahead of market clash with Ionis
Sep 3, 2024 9:27am
Arrowhead RNAi med lowers triglycerides in phase 3
Jun 3, 2024 9:54am
Ionis reveals oasis for HAE patients as RNA med reduces attacks
May 31, 2024 10:40am
Biogen walks away from Ionis-partnered ALS, Angelman prospects
May 16, 2024 9:24am